CBRE Group
CBRE
$152.10
+0.20%
CBRE Group is the world's largest commercial real estate services and investment firm, offering brokerage, leasing, facilities and project management, valuation, mortgage services, and investment management to occupiers and investors across every major property type. As an industry leader with over 155,000 employees serving clients in more than 100 countries, CBRE's scale and global footprint provide a distinct competitive advantage. The current investor narrative centers on the company's recovery from a cyclical downturn in transaction volumes, with recent quarterly results showing strong revenue growth and margin expansion, while the stock has underperformed the broader market over the past year, creating a potential value opportunity. Debates revolve around the sustainability of the rebound in commercial real estate activity and the impact of higher interest rates on transaction volumes and property values.…
CBRE
CBRE Group
$152.10
Investment Opinion: Should I buy CBRE Today?
Rating: Buy. The thesis is that CBRE is a cyclical recovery play with strong revenue acceleration and margin expansion, trading at a reasonable forward PE of 16.8x. The analyst consensus is 'Buy' with an average target of $182.50, implying 20% upside. The stock is well-positioned to benefit from the ongoing recovery in commercial real estate activity.
Sign up to view all
CBRE 12-Month Price Forecast
The AI assessment is bullish, driven by strong revenue acceleration and margin expansion, which are likely to continue as the commercial real estate cycle recovers. The forward valuation is reasonable, and analyst sentiment is positive. However, the medium confidence reflects the uncertainty around interest rates and the sustainability of the recovery. If revenue growth continues above 15% and margins hold, the stock could re-rate higher. Conversely, any signs of deceleration would warrant a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CBRE Group's 12-month outlook, with a consensus price target around $182.50 and implied upside of +20.0% versus the current price.
Average Target
$182.50
0 analysts
Implied Upside
+20.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$144 - $200
Analyst target range
The target price range spans from $144.00 (low) to $200.00 (high), with the high target implying a 31.5% upside and the low target implying a -5.3% downside. The wide spread of $56 suggests significant uncertainty about the pace of recovery in commercial real estate. The high target likely assumes a robust rebound in transaction volumes and margin expansion, while the low target may reflect concerns about sustained high interest rates or a slower recovery. The recent pattern of upgrades and positive ratings indicates improving sentiment among analysts, which supports the bullish consensus.
Bulls vs Bears: CBRE Investment Factors
The bull case is currently stronger, driven by accelerating revenue growth, margin expansion, and a compelling forward valuation. However, the bear case highlights the high trailing PE, leverage, and interest rate sensitivity. The central tension is whether the cyclical recovery in commercial real estate is sustainable or a temporary rebound. If transaction volumes continue to recover, the forward PE of 16.8x will prove undervalued, but if rates stay high, the recovery could stall, leading to earnings disappointment. The stock's underperformance versus the market suggests that investors are not yet fully convinced, but the recent price recovery and analyst upgrades indicate improving sentiment.
Bullish
- Strong Revenue Acceleration: Q1 2026 revenue surged 18.2% YoY to $10.527B, up from $8.91B in Q1 2025, marking the fourth consecutive quarter of sequential growth. This acceleration signals a robust cyclical recovery in commercial real estate activity, with broad-based strength across Advisory Services ($2.024B) and Project Management ($1.838B).
- Margin Expansion and Profitability: Operating margin improved to 4.85% in Q1 2026 from 3.10% in Q1 2025, while net income jumped to $318M from $163M, a 95% increase. This demonstrates significant operating leverage as revenue scales, with EPS rising to $1.08 from $0.54.
- Analyst Consensus and Upside: The average analyst target is $182.50, implying 20% upside from the current price of $152.10, with a high target of $200 (31.5% upside). The consensus rating is 'Buy' with a mean score of 1.54, reflecting strong positive sentiment among analysts.
- Attractive Forward Valuation: The forward PE of 16.8x is significantly lower than the trailing PE of 41.4x, indicating the market expects substantial earnings growth. The PEG ratio of 1.82 suggests the stock is reasonably valued relative to its growth prospects, not overextended.
Bearish
- High Trailing PE and Earnings Volatility: The trailing PE of 41.4x is elevated, reflecting the cyclical trough in earnings. Net income has been volatile, swinging from $487M in Q4 2024 to $215M in Q2 2025, indicating that the current earnings recovery may not be linear.
- Underperformance vs. Market: CBRE's 1-year price change is -4.4% versus the S&P 500's +20.5%, a relative underperformance of nearly 25 percentage points. This suggests persistent investor skepticism about the sustainability of the recovery.
- High Debt-to-Equity Ratio: The debt-to-equity ratio of 1.13 indicates significant leverage, which could strain cash flows if interest rates remain high. Interest expense was $59M in Q1 2026, and a prolonged high-rate environment could pressure margins.
- Sensitivity to Interest Rates: Commercial real estate transaction volumes are highly sensitive to interest rates. With the Fed funds rate potentially staying elevated, the recovery in transaction activity could stall, as evidenced by the stock's beta of 1.19, which amplifies market volatility.
CBRE Technical Analysis
CBRE's 1-year price change of -4.4% indicates a modest downtrend, but the stock is currently trading at $152.10, which is 87% of its 52-week range (low of $121.69, high of $174.27), suggesting it has recovered significantly from its lows. The stock's 6-month change of +3.5% shows a gradual recovery, while the 1-year underperformance versus the S&P 500 (which gained 20.5%) highlights relative weakness. The current price is near the upper end of its 52-week range, indicating a potential breakout or overextension, but the long-term trend remains below the high.
Beta
1.19
1.19x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$122-$174
Price range past year
Annual Return
-4.4%
Cumulative gain past year
| Period | CBRE Return | S&P 500 |
|---|---|---|
| 1m | +10.9% | +3.6% |
| 3m | +16.0% | +2.7% |
| 6m | +3.5% | +11.4% |
| 1y | -4.4% | +18.7% |
| ytd | -5.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRE Fundamental Analysis
CBRE's revenue trajectory is strongly positive, with Q1 2026 revenue of $10.527 billion, up 18.2% year-over-year, and a clear acceleration from the prior year's quarters (Q1 2025: $8.91B, Q2 2025: $9.753B, Q3 2025: $10.258B, Q4 2025: $11.629B). The growth is broad-based, with Advisory Services contributing $2.024 billion and Project Management $1.838 billion in the latest quarter, while Real Estate Investments added $199 million. This acceleration suggests a cyclical recovery in commercial real estate activity, which is a positive sign for the investment case.
Quarterly Revenue
$10.5B
2026-03
Revenue YoY Growth
+18.1%
YoY Comparison
Gross Margin
17.6%
Latest Quarter
Free Cash Flow
$897000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRE Overvalued?
Given that CBRE has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 41.4x, while the forward PE is 16.8x, indicating the market expects significant earnings growth. The gap between trailing and forward PE implies that the market is pricing in a substantial recovery in earnings, which aligns with the recent revenue acceleration. The PEG ratio of 1.82 suggests that the stock is reasonably valued relative to its expected growth rate, though it is not cheap.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~74x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks: CBRE carries a debt-to-equity ratio of 1.13, indicating substantial leverage that could strain cash flows if interest rates remain elevated. Interest expense of $59M in Q1 2026 is manageable but could grow if rates rise. The company's net margin is thin at 2.85% (TTM), leaving little room for error if revenue growth decelerates. Free cash flow of $897M (TTM) is positive but modest relative to market cap, and the payout ratio is zero, so no dividend cushion exists. Earnings volatility is high, with quarterly net income ranging from $130M to $487M over the past eight quarters, reflecting the cyclicality of the business.
FAQ
The key risks are: (1) Interest rate risk - high rates could stall transaction volumes, as seen in the sensitivity of the business to borrowing costs. (2) Cyclical risk - commercial real estate is cyclical, and a downturn could lead to earnings volatility. (3) Leverage risk - the debt-to-equity ratio of 1.13 increases financial vulnerability. (4) Competitive risk - disruption from technology platforms could erode market share. The most severe risk is a prolonged high-rate environment, which could lead to a 20-50% downside.
The 12-month forecast is positive. The base case (50% probability) targets $160-$180, with the average analyst target at $182.50. The bull case (30% probability) targets $180-$200, driven by a strong recovery and margin expansion. The bear case (20% probability) targets $120-$140, if the recovery stalls. The most likely scenario is the base case, with moderate growth and a stock price around $170. The key assumption is that interest rates remain stable and the commercial real estate recovery continues.
CBRE is undervalued on a forward basis. The trailing PE of 41.4x is high, but the forward PE of 16.8x indicates that the market expects significant earnings growth. The PEG ratio of 1.82 suggests the stock is reasonably priced relative to its growth rate. Compared to the broader market, CBRE's forward PE is lower than the S&P 500's average, and the stock trades at a discount to its historical average forward PE. The market is pricing in a strong recovery, but if the recovery materializes, the stock has room to re-rate higher.
Yes, CBRE is a good buy for investors with a medium-to-long-term horizon. The stock offers a 20% upside to the average analyst target of $182.50, and the forward PE of 16.8x is attractive given the expected earnings growth. The main risk is a slowdown in the commercial real estate recovery, which could lead to a 20% downside to the 52-week low of $121.69. However, the recent revenue acceleration and margin expansion suggest the recovery is on track, making the risk/reward favorable.
CBRE is suitable for long-term investment, given its cyclical nature and the expected multi-year recovery in commercial real estate. The stock has a beta of 1.19, indicating higher volatility, which makes it less suitable for short-term trading. The company does not pay a dividend, so returns depend on capital appreciation. A minimum holding period of 3-5 years is recommended to ride out the cycle and capture the full earnings recovery. Short-term traders may find opportunities in the volatility, but the fundamental thesis is best realized over a longer horizon.